Effects of early vs. late initiation of levodopa treatment in hemiparkinsonian rats

European Journal of Neuroscience

Volumn 30, Issue 5, 2009, Pages 823-832

  Marin, C ^a,b   Aguilar, E ^a   Mengod, G ^a,b   Cortes R ^a,b   Obeso, J A ^b,c  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^c UNIVERSITY OF NAVARRA   (Spain)

Author keywords

Cytochrome oxidase; Dyskinesias; Levodopa; Parkinson's disease; Preprodynorphin; Preproenkephalin

Indexed keywords

BENSERAZIDE PLUS LEVODOPA; CYTOCHROME C OXIDASE; GLUTAMATE DECARBOXYLASE 67; PREPRODYNORPHIN; PREPROENKEPHALIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BASAL GANGLION; CIRCLING BEHAVIOR; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFECT; DYSKINESIA; MALE; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; NUCLEOTIDE SEQUENCE; PARKINSONISM; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA; THERAPY DELAY; ZONA RETICULATA;

ANIMALS; CORPUS STRIATUM; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DYNORPHINS; DYSKINESIAS; ELECTRON TRANSPORT COMPLEX IV; ENKEPHALINS; GLUTAMATE DECARBOXYLASE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LEVODOPA; MALE; NEURONS; OXIDOPAMINE; PARKINSON DISEASE, SECONDARY; PROTEIN PRECURSORS; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; SUBSTANTIA NIGRA; SUBTHALAMIC NUCLEUS;

EID: 69549129510     PISSN: 0953816X     EISSN: 14609568     Source Type: Journal    
DOI: 10.1111/j.1460-9568.2009.06877.x     Document Type: Article

References (46)

1. Agid, Y. (1998) Levodopa: is toxicity a myth? Neurology, 50, 858 863.
2. Andersson, M., Hilbertson, A. Cenci, M.A. (1999) Striatal fos B expression is causally linked with L-Dopa-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease. Neurobiol. Dis., 6, 461 474.
3. Bezard, E., Crossman, A.R., Gross, C.E. Brotchie, J.M. (2001) Structures outside the basal ganglia may compensate for dopamine loss in the presymptomatic stages of Parkinson's disease. FASEB J., 15, 1092 1094.
4. Blunt, S.B., Jenner, P. Marsden, C.D. (1993) Suppressive effect of L-Dopa on dopamine cells remaining in the ventral tegmental area of rats previously exposed to the neurotoxin 6-hydroxydopamine. Mov. Disord., 8, 129 133.
5. Campbell, G.A., Eckardt, M.J. Weight, F.F. (1985) Dopaminergic mechanisms in subthalamic nucleus of rat: analysis using horseradish peroxidase and microinontophoresis. Brain Res., 333, 261 270.
6. Cedarbaum, J.M., Gandy, S.E. McDowell, F.H. (1991) "Early" initation of levodopa treatment does not promote the development of motor response fluctuations, dyskinesias, or dementia in Parkinson's disease. Neurology, 41, 622 629.
7. Cenci, M.A., Lee, C.S. Björklund, A. (1998) Levodopa-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin-and glutamic acid decarboxylase mRNA. Eur. J. Neurosci., 10, 2694 2706.
8. Chan, P.L., Nutt, J.G. Holford, N.H. (2007) Levodopa slows progression of Parkinson's disease: external validation by clinical trial simulation. Pharm. Res., 24, 791 802.
9. Clarke, C.E. (2008) Are delayed-start design trials to show neuroprotection in Parkinson's disease fundamentally flawed? Mov. Disord., 23, 784 789.
10. Corona-Morales, A.A., Castell, A. Zhang, L. (2000) L-Dopa-induced neurotoxic and apoptotic changes on cultures chromaffin cells. Neuroreport, 11, 503 506.
11. Cotzias, G.C., van Woert, M.H. Schiffer, L.M. (1967) Aromatic amino acids and modification of parkinsonism. N. Engl. J. Med., 276, 374 379.
12. Diamond, S.G., Markham, C.H., Hoehn, M.M., McDowell, F.H. Muenter, M.D. (1987) Multi-center study of Parkinson mortality with early versus later dopa treatment. Ann. Neurol., 22, 8 12.
13. Fahn, S. (1999) Parkinson's disease, the effect of levodopa, and the ELLDOPA trial. Earlier vs later L-Dopa. Arch. Neurol., 56, 529 535.
14. Flores, G., Llang, J.J., Sierra, A., Martinez-Fong, D., Quirion, R., Aceves, J. Srivastava, L.K. (1999) Expression of dopamine receptors in the subthalamic nucleus of the rat: characterization using reverse transcription-polymerase chain reaction and autoradiography. Neuroscience, 91, 549 556.
15. Fukuda, T., Watabe, K. Tanaka, J. (1996) Effects of bromocriptine and/or L-Dopa on neurons in substantia nigra of MPTP-treated C57BL/6 mice. Brain Res., 29, 274 276.
16. Han, S.K., Mytilineou, C. Cohen, G. (1996) L-Dopa up-regulates glutathione and protects mesencephalic cultures against oxidative stress. J. Neurochem., 66, 501 510.
17. Hassani, O.K. Féger, J. (1999) Effects of intrasubthalamic injection of dopamine receptor agonists on subthalamic neurons in normal and 6-hydroxydopamine-lesioned rats: an electrophysiological and c-Fos study. Neuroscience, 92, 533 543.
18. Hassani, O.K., Francois, C., Yelnik, J. Féger, J. (1997) Evidence for a dopaminergic innervation of the subthalamic nucleus in the rat. Brain Res., 749, 88 94.
19. Hedreen, J.C. (1999) Tyrosine hydroxylase-immunoreactive elements in the human globus pallidus and subthalamic nucleus. J. Comp. Neurol., 409, 400 410.
20. Hefti, F., Melamed, E. Wurtman, R.J. (1981) The site of dopamine formation in rat striatum after L-Dopa administration. J. Pharmacol. Exp. Ther., 217, 189 197.
21. Henry, B., Crossman, A.R. Brotchie, J.M. (1999) Effect of repeated L-Dopa, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat. Exp. Neurol., 155, 204 220.
22. Hornykiewicz, O. Kish, S.J. (1987) Biochemical pathophysiology of Parkinson's disease. Adv. Neurol., 45, 1 34.
23. Jankovic, J. (2008) Parkinson's disease: clinical features and diagnosis. J. Neurol. Neurosurg. Psychiatry, 79, 368 376.
24. Jankovic, J., Watts, R.L., Martin, W. Boroojerdi, B. (2007) Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson disease. Arch. Neurol., 64, 676 682. (Pubitemid 46789833)
25. Lavoie, B., Smith, Y. Parent, A. (1989) Dopaminergic innervation of the basal ganglia in the squirrel monkey as revealed by tyrosine hydroxylase immunohistochemistry. J. Comp. Neurol., 289, 36 52.
26. Lundblad, M., Andersson, M., Winkler, C., Kirik, D., Wierup, N. Cenci, M.A. (2002) Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur. J. Neurosci., 15, 120 132.
27. Lundblad, M., Bjerkén, S., Cenci, M.A., Pomerleau, F., Gerhardt, G.A. Stömberg, I. (2009) Chronic intermittent L-Dopa treament induces changes in dopamine release. J. Neurochem., 108, 998 1008.
28. Marin, C., Aguilar, E., Mengod, G., Cortés, R. Obeso, J.A. (2007) Concomitant short- and long-duration response to levodopa in the 6-OHDA-lesioned rat: a behavioural and molecular study. Eur. J. Neurosci., 25, 259 269.
29. Mehta, A., Thermos, K. Chesselet, M.F. (2000) Increased behavioral response to dopaminergic stimulation of the subthalamic nucleus after nigrostriatal lesions. Synapse, 37, 298 307.
30. Mena, M.A., Davila, V. Sulzer, D. (1997) Neurotrophic effects of L-Dopa in postnatal midbrain dopamine neuron/cortical astrocyte cocultures. J. Neurochem., 69, 1398 1408.
31. Murer, M.G., Dziewczapolski, G., Menalled, L.B., Garcia, M., Agid, Y., Gershanik, O. Raisman-Vozari, R. (1998) Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions. Ann. Neurol., 43, 561 575.
32. Mytilineou, C., Han, S.K. Cohen, G. (1993) Toxic and protective effects of L-Dopa on mesencephalic cell cultures. J. Neurochem., 61, 1470 1478.
33. Obeso, J.A., Rodríguez-Oroz, M., Marin, C., Alonso, F., Zamarbide, I., Lanciego, J.L. Rodríguez-Díaz, M. (2004) The origin of motor fluctuations in Parkinson's disease: importance of dopaminergic innervation and basal ganglia circuits. Neurology, 62 (Suppl 1 S17 S30.
34. Olanow, C.W., Watts, R.L. Koller, W.C. (2001) An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology, 56 (11 Suppl 5 S1 S88.
35. Papa, S.M., Engber, T.M., Kask, A.M. Chase, T.N. (1994) Motor fluctuations in levodopa-treated parkinsonian rats: relation to lesion extent and treatment duration. Brain Res., 662, 69 74.
36. Parkinson Study Group (2004) Levodopa and the progression of Parkinson's disease. N. Engl. J. Med., 351, 2498 2508.
37. Parry, T.J., Eberle-Wang, K., Lucki, I. Chesselet, M.E. (1994) Dopaminergic stimulation of subthalamic nucleus elicits oral dyskinesia in rats. Exp. Neurol., 128, 181 190.
38. Paxinos, G. Watson, C. (1986) The Rat Brain in Stereotaxic Coordinates. Academic Press, New York.
39. Rajput, A.H., Fenton, M., Birdi, S. Macaulay, R. (1997) Is levodopa toxic to human substantia nigral? Mov. Disord., 12, 634 638.
40. Rascol, O., Brooks, D.J., Melamed, E., Oertel, W., Poewe, W., Stocchi, F. Tolosa, E. (2005) LARGO study group. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in adjunct therapy with Rasagiline given once daily, study): a randomised, double-blind, parallel-group trial. Lancet, 365, 947 954.
41. Rodríguez, M.C., Obeso, J.A. Olanow, C.W. (1998) Subthalamic nucleus-mediated excitotoxicity in Parkinson's disease: a target for neuroprotection. Ann. Neurol., 44 (3 Suppl 1 S175 S188.
42. Schapira, A.H. (2008) Progress in neuroprotection in Parkinson's disease. Eur. J. Neurol., 15 (Suppl 1 5 13.
43. Schapira, A.H. Obeso, J.A. (2006) Timing of treatment initiation in Parkinson's disease: a need for reappraisal? Ann. Neurol., 59, 559 562.
44. Shoulson, I., Oakes, D., Fahn, S., Lang, A., Langston, J.W., LeWitt, P., Olanow, C.W., Penney, J.P., Tanner, C., Kieburtz, K., Rudolph, A. the Parkinson Study Group (2002) Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Ann. Neurol., 51, 604 612.
45. Stacy, M. Galbreath, A. (2008) Optimizing long-term therapy for Parkinson disease: options for treatment-associated dyskinesia. Clin. Neuropharmacol., 31, 120 125.
46. Ziv, I., Zilkha-Falb, R., Offen, D., Shirvan, A., Barzilai, A. Melamed, R. (1997) Levodopa induces apoptosis in cultured neuronal cells-a possible accelerator of nigrostriatal degeneration in Parkinson's disease? Mov. Disord., 12, 17 23.